Bulletin
Investor Alert

Oct. 19, 2021, 7:20 a.m. EDT

FDA committee says it’s safe for all adults who got J&J’s COVID-19 vaccine to get a booster

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    Moderna Inc. (MRNA)
  • X
    BioNTech SE ADR (BNTX)

or Cancel Already have a watchlist? Log In

Jaimy Lee

The Food and Drug Administration should authorize a second “booster” dose of Johnson & Johnson’s /zigman2/quotes/201724570/composite JNJ -0.65% COVID-19 vaccine for adults who were initially vaccinated with this vaccine, according to a group of scientists and clinicians that advises the regulator.

The FDA’s Vaccines and Related Biological Products Advisory Committee voted 19-0 that allowing adults who were initially vaccinated with the J&J shot to get a booster is safe and effective. Their recommendation is based on giving a booster to those 18 years old and older at least two months after they got their first shot.

“This does look more like a two-dose vaccine,” Dr. Michael Nelson, a professor of medicine at UVA Health and the UVA School of Medicine and a temporary voting member of the FDA committee, said Friday during the meeting.

One difference with this booster recommendation is that the group of people who would qualify for the J&J booster can get it two months after getting their first dose, compared with six months after the primary series of shots for the mRNA vaccines developed by Moderna Inc. /zigman2/quotes/205619834/composite MRNA +20.57% and BioNTech SE /zigman2/quotes/214419716/composite BNTX +14.19% /Pfizer Inc. /zigman2/quotes/202877789/composite PFE +6.11% .

If the FDA follows the advice of the committee, which it is not required to do but often does, it means that all three COVID-19 vaccines that are available in the U.S. have authorized boosters, with the caveat that there are restrictions in place on who can get a mRNA booster.

The mRNA boosters are reserved at this time for people older than 65 years old, adults who are at high risk of severe disease, and those who face higher exposure to the virus because of their jobs.

About 15 million people in the U.S. have received the J&J’s adenovirus-based COVID-19 vaccine.

J&J’s stock is up 2.6% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -2.27% has gained 18.1%.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 159.20
-1.04 -0.65%
Volume: 8.52M
Nov. 26, 2021 1:10p
P/E Ratio
23.79
Dividend Yield
2.66%
Market Cap
$421.85 billion
Rev. per Employee
$613,918
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 329.63
+56.24 +20.57%
Volume: 35.90M
Nov. 26, 2021 1:00p
P/E Ratio
20.24
Dividend Yield
N/A
Market Cap
$110.85 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 348.00
+43.24 +14.19%
Volume: 11.03M
Nov. 26, 2021 1:00p
P/E Ratio
10.05
Dividend Yield
N/A
Market Cap
$73.91 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 54.00
+3.11 +6.11%
Volume: 66.56M
Nov. 26, 2021 1:10p
P/E Ratio
16.03
Dividend Yield
2.89%
Market Cap
$285.64 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,594.62
-106.84 -2.27%
Volume: 2.10B
Nov. 26, 2021 2:12p
loading...

Get news alerts on Johnson & Johnson — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.